Moderna Inc (MRNA)vsNuCana PLC (NCNA)
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
NCNA
NuCana PLC
$1.47
-3.92%
HEALTHCARE · Cap: $6.33M
Smart Verdict
WallStSmart Research — data-driven comparison
NCNA leads profitability with a 0.0% profit margin vs -141.4%. NCNA earns a higher WallStSmart Score of 26/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NCNA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Intrinsic value data unavailable for NCNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NCNA
The strongest argument for NCNA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NCNA
The primary concerns for NCNA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NCNA is a value play — different risk/reward profiles.
NCNA carries more volatility with a beta of 2.22 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NCNA generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
NCNA scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
NuCana PLC
HEALTHCARE · BIOTECHNOLOGY · USA
NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?